Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVI Global Trust Regulatory News (AGT)

Share Price Information for AVI Global Trust (AGT)

Share Price is delayed by 15 minutes
Get Live Data
257.50    -2.50 (-0.96%)
Bid:
258.00
Ask:
258.50
Spread: 0.50 (0.194%)
Market Cap: £1.03b
AGT Live PriceLast checked at - London Stock Exchange

Intraday AVI Global Trust Share Chart

Monthly Factsheet

Today 16:20

RNS Number : 4561H
AVI Global Trust PLC
08 June 2026
 

 

AVI GLOBAL TRUST PLC

 

Monthly Update

 

AVI Global Trust plc (the "Company") presents its Update, reporting performance figures for the month ended 31 May 2026.

 

This Monthly Newsletter is available on the Company's website at: AGT-MAY-2026.pdf

 

This investment management report relates to performance figures to 31 May 2026.

 

Total Returns (%)

Month

1Y

5Y

10Y

NAV p/s1

3.0

11.8

49.0

219.4

MSCI ACWI2

5.8

30.1

81.0

259.7

MSCI ACWI ex US2

5.1

31.9

59.4

173.6

 

All performance shown net of fees in GBP Total Return as at 31/05/2026.

1Net Asset Value cum-fair.

2From 1st October 2023, the comparator benchmark was changed to the MSCI ACWI Index. Prior to this, from 1st October 2013, the comparator benchmark was the MSCI ACWI ex US Index.

Source: Morningstar, S&P Capital IQ

 

Manager's Comment

AVI Global Trust's (AGT) NAV increased by +3.0% in May 2026.

Samsung C&T was the standout performer, adding +214bps to NAV with a share price return of +45%. Vivendi (+97bps) and Kyocera (+58bps) also contributed strongly.

At the other end of the ledger, Hyosung Corp suffered the newsletter curse and shaved -57bps from returns. Chrysalis (-56bps) and Amorepacific (-42bps) also detracted.

Korea

We introduced the position in Samsung C&T in the December 2025 newsletter. Since then, the shares have risen +81%, as a +72% increase in the NAV has been complemented by a narrowing of the discount to 55% from 57%.

In May alone the stock rose +45%, adding +214bps to AGT's NAV. As we will come onto, it is interesting and notable that our other Korean holdings did not register positive returns over the month.

Central to this, has been Samsung Electronics ("SEC") which accounts for 61% of Samsung C&Ts NA and returned +42% over the month.

The semiconductor industry has historically been a deeply cyclical one. The vicissitudes and resulting mergers and bankruptcies have taken the world from c.30 DRAM players to just three today: Samsung Electronics, SK Hynix and Micron.

Against this constrained supply the advent of AI has sent demand parabolic, with a memory super-cycle driven by accelerating High Bandwidth Memory ("HBM") demand, pushing memory prices higher. One metric which illustrates the immense magnitude of this earnings inflection is the upward revision to Samsung's 2026 consensus EBIT, where the sell-side had initially been modelling c. +137% YoY growth at the start of 2026 with expectations since revised up c.+700% YoY. In $ terms, expectations for EBIT in 2026 have gone from $72bn to $230bn - and that's even after recent labour negotiations that resulted in an average $400k profit bonus per employee.

The market is increasingly convinced that this memory upcycle may prove more durable than previous ones. Supply-demand analysis points to persistent DRAM and NAND undersupply extending through at least 2028. This leverage has in turn led to binding long-term agreements ("LTAs") across the sector, where rather than just being volume-based, contracts have embedded fixed price protections, enhancing earnings visibility, reducing cyclicality and improving through cycle returns on capital. In turn, investors are debating whether these developments warrant such companies to be valued on an earnings basis - as opposed to a price to book basis. At c.6x 2026e PE there is certainly room for SEC to continue to re-rate, particularly as investors appreciate the advancements the company has made in HBM.

That said, we do not believe the leopard can entirely change its spots. The industry remains cyclical and prone to great booms and busts and even with improved LTA contracts the current super cycle will at some point turn. Calling when this will be is of course the billion (trillion!?) dollar question and one the many market participants are trying to figure out.

Turning to Samsung C&T itself, the persistently wide 55% discount at which the shares trade reflects management's inaction over the discount and a historically unambitious approach to capital allocation. We continue to believe that the company can do more to replicate the success of peers in closing their discounts, and this remains a core focus of our ongoing engagement with management.

In terms of the wider Korean opportunity set, over the month, the KOSPI achieved a new all-time high of 8,000, returning +29%. However, this headline price performance increasingly tells the story of SEC and SK Hynix. The two memory companies now account for c.53% of the index and have driven the bulk of this year's gains. Strip them out and the rest of the market delivered only modest single-digit returns in May. Similar patterns are observed in our recent Korea performance, and really this serves as an allegory for the wider market.

The broader Korean market remains deeply undervalued, with two thirds of all KOSPI constituents still trading below book value, far higher than in markets such as Japan, Europe or the US. The Korea discount has not yet been eliminated so much as masked by the memory cycle.

Unlocking the next leg of performance will require the government and regulator to push further on the Value-Up agenda, from more prescriptive capital allocation and governance disclosures to enforcement of the new anti-stock price suppression framework and mandatory tender-offer rules - which together could catalyse a broader re-rating of the many high quality Korean businesses that remain chronically overlooked by global investors.

During the month we spent considerable time in Korea meeting companies and other investors, and we return with conviction that the opportunity is as compelling as it has been at any point in our time following this market.

Vivendi:

We last wrote about Vivendi in the March newsletter, yet it warrants a quick update. Since then, the stock is up +32%, as a +19% increase in the NAV has been buoyed by a narrowing of the discount to 43% from 49% (a return of +11%).

As we wrote at the time, in April UMG (86% of NAV) was subject to a proposed transaction from Pershing Square ("PS") at an ostensible +78% premium, by way of a proposed merger with Pershing Square SPARC Holdings, a blank cheque acquisition company. In May 2026 it was announced that Bolloré - and in- turn the UMG board - have rejected this proposal. With that said, we do believe the PS offer highlights UMG's deep undervaluation -their public presentation articulated the reasons for this well and provided sensible remedies too. Whilst the transaction itself has been rejected, UMG management appear to be heeding some of the advice, announcing plans to monetise half its stake in Spotify, having doubled the buyback from €500m to €1bn, and making some improvements to financial disclosure. The board's statement rejecting the PS offer highlighted that adjusted EBITDA had grown nearly +70% since IPO. The share price however is some -14% from where it closed on the day of the IPO. We believe the onus is on management - and Bolloré - to prove they can unlock shareholder value. Post month-end this feels particularly acute with the news that PS have exited their position in UMG entirely in an accelerated book build, with UMG buying back €250m of stock. We believe their sale speaks to the level of deep frustration at the status quo - which we share.

Turning to Vivendi, the discount contracted 500bps to 43% in the last two weeks of May. The proximate cause relates to an ongoing legal battle pertaining as to whether Vincent Bolloré held de-facto control of Vivendi at the time of the 2024 split, and as such whether he should be obligated to make a mandatory offer for the company (which we have discussed here and here). We expect an outcome from the trial in early July this year but court reports suggest important new evidence has come to light and the Advocate General has reportedly argued in favour of the notion of Bolloré being in control, The market has started to price some possibility of a more favourable outcome for Vivendi minorities. We expect there to be many twists and turns - and potentially appeals yet - but we believe at a 43% discount, investors are placing a fairly low probability on a mandatory fair value take private offer.

The combination of the still wide discount and the significant potential upside from UMG provide the ingredients for attractive returns from here.

Contributors / Detractors (in GBP)4

 

Largest Contributors

1- month contribution

bps

% Weight3

Samsung C&T

214

6.7

Vivendi

97

6.1

Kyocera Corp

58

2.7

Partners Group PE

47

3.7

Mitsubishi Logistics

37

5.8

 

Largest Detractors

1- month contribution

bps

% Weight3

Hyosung Corp

-57

3.6

Chrysalis Investments

-56

5.4

Amorepacific Holdings

-42

1.7

HD Hyundai

-34

2.4

Daou Technology

-25

1.4

 

3All Figures shown as % of Net Asset Value

4Contributors and detractors from Factset

 

 

MUFG Corporate Governance Limited

Corporate Secretary

 

8 June 2026

 

LEI: 213800QUODCLWWRVI968

 

The content of the Company's web-pages and the content of any website or pages which may be accessed through hyperlinks on the Company's web-pages, other than the content of the Newsletter referred to above, is neither incorporated into nor forms part of the above announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCUPURGQUPQGAR
Date   Source Headline
8th Jun 20264:20 pmRNSMonthly Factsheet
8th Jun 20261:48 pmRNSNet Asset Value(s)
5th Jun 20265:13 pmRNSTransaction in Own Shares
5th Jun 202612:41 pmRNSNet Asset Value(s)
4th Jun 20261:04 pmRNSNet Asset Value(s)
4th Jun 20267:00 amRNSHalf-year Financial Report
3rd Jun 20261:50 pmRNSNet Asset Value(s)
2nd Jun 20261:23 pmRNSNet Asset Value(s)
1st Jun 20265:17 pmRNSTransaction in Own Shares
1st Jun 20262:58 pmRNSNet Asset Value(s)
1st Jun 202610:22 amRNSTotal Voting Rights
29th May 202611:31 amRNSNet Asset Value(s)
28th May 20261:55 pmRNSNet Asset Value(s)
27th May 20265:05 pmRNSTransaction in Own Shares
27th May 20262:54 pmRNSNet Asset Value(s)
26th May 20265:41 pmRNSTransaction in Own Shares
26th May 20261:15 pmRNSNet Asset Value(s)
22nd May 20265:12 pmRNSTransaction in Own Shares
22nd May 20261:20 pmRNSNet Asset Value(s)
21st May 20265:11 pmRNSTransaction in Own Shares
21st May 202611:56 amRNSNet Asset Value(s)
20th May 20261:55 pmRNSNet Asset Value(s)
19th May 20265:17 pmRNSTransaction in Own Shares
19th May 202611:43 amRNSNet Asset Value(s)
18th May 20261:06 pmRNSNet Asset Value(s)
15th May 202612:20 pmRNSNet Asset Value(s)
14th May 20262:21 pmRNSMonthly Factsheet
14th May 20261:03 pmRNSNet Asset Value(s)
13th May 202612:51 pmRNSNet Asset Value(s)
12th May 20261:38 pmRNSNet Asset Value(s)
11th May 20265:30 pmRNSTransaction in Own Shares
11th May 20261:37 pmRNSNet Asset Value(s)
8th May 20261:43 pmRNSNet Asset Value(s)
7th May 20265:30 pmRNSTransaction in Own Shares
7th May 202612:42 pmRNSNet Asset Value(s)
6th May 20265:23 pmRNSTransaction in Own Shares
6th May 202612:32 pmRNSNet Asset Value(s)
5th May 20261:12 pmRNSNet Asset Value(s)
1st May 202612:33 pmRNSNet Asset Value(s)
1st May 20269:58 amRNSTotal Voting Rights
30th Apr 20261:45 pmRNSNet Asset Value(s)
29th Apr 20265:37 pmRNSTransaction in Own Shares
29th Apr 202612:23 pmRNSNet Asset Value(s)
28th Apr 20265:12 pmRNSTransaction in Own Shares
28th Apr 202612:18 pmRNSNet Asset Value(s)
27th Apr 20265:09 pmRNSTransaction in Own Shares
27th Apr 20261:10 pmRNSNet Asset Value(s)
27th Apr 202610:30 amRNSCompliance with Market Abuse Regulations
24th Apr 20265:05 pmRNSTransaction in Own Shares
24th Apr 202612:25 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.